Ganesan G, Rangasami R, Chandrasekharan A, Marreddy S, Ramachandran R
Asian J Neurosurg. 2025; 20(1):34-42.
PMID: 40041591
PMC: 11875706.
DOI: 10.1055/s-0044-1790508.
Furth N, Cohen N, Spitzer A, Salame T, Dassa B, Mehlman T
Proc Natl Acad Sci U S A. 2025; 122(1):e2403862122.
PMID: 39793065
PMC: 11725805.
DOI: 10.1073/pnas.2403862122.
Darlix A, Preusser M, Hervey-Jumper S, Shih H, Mandonnet E, Taylor J
Neurooncol Pract. 2025; 12(Suppl 1):i6-i18.
PMID: 39776530
PMC: 11703370.
DOI: 10.1093/nop/npae104.
Guan X, Hu B, Zheng W, Zhai H, Han X, Hu C
Sci Rep. 2024; 14(1):29930.
PMID: 39622933
PMC: 11611908.
DOI: 10.1038/s41598-024-73088-2.
Nassihi A, Duffau H
Acta Neurochir (Wien). 2024; 166(1):425.
PMID: 39465448
DOI: 10.1007/s00701-024-06321-6.
Diffuse low-grade glioma: What is the optimal linear measure to assess tumor growth?.
Dos Santos T, Deverdun J, Chaptal T, Darlix A, Duffau H, Van Dokkum L
Neurooncol Adv. 2024; 6(1):vdae044.
PMID: 39071735
PMC: 11274528.
DOI: 10.1093/noajnl/vdae044.
Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors.
Cho N, Le V, Sanvito F, Oshima S, Harper J, Chun S
Neuro Oncol. 2024; 26(10):1823-1836.
PMID: 38808755
PMC: 11449060.
DOI: 10.1093/neuonc/noae097.
IDH inhibition in gliomas: from preclinical models to clinical trials.
Ruda R, Horbinski C, van den Bent M, Preusser M, Soffietti R
Nat Rev Neurol. 2024; 20(7):395-407.
PMID: 38760442
DOI: 10.1038/s41582-024-00967-7.
Juvenile pilocytic astrocytoma in a child with a prior normal neonatal brain MRI.
Ho C, Crawford J
BMJ Case Rep. 2024; 17(4).
PMID: 38649241
PMC: 11043744.
DOI: 10.1136/bcr-2024-260174.
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions.
Zinsz A, Pouget C, Rech F, Taillandier L, Blonski M, Amlal S
Eur J Nucl Med Mol Imaging. 2024; 51(9):2672-2683.
PMID: 38637354
DOI: 10.1007/s00259-024-06720-y.
Diagnostic and Therapeutic Issues in Glioma Using Imaging Data: The Challenge of Numerical Twinning.
Guillevin R, Naudin M, Fayolle P, Giraud C, Le Guillou X, Thomas C
J Clin Med. 2023; 12(24).
PMID: 38137775
PMC: 10744312.
DOI: 10.3390/jcm12247706.
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Delobel T, Ayala-Hernandez L, Bosque J, Perez-Beteta J, Chulian S, Garcia-Ferrer M
PLoS Comput Biol. 2023; 19(11):e1011208.
PMID: 37983271
PMC: 10695391.
DOI: 10.1371/journal.pcbi.1011208.
Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma.
Bhatia A, Moreno R, Reiner A, Nandakumar S, Walch H, Thomas T
Clin Cancer Res. 2023; 30(1):106-115.
PMID: 37910594
PMC: 10841595.
DOI: 10.1158/1078-0432.CCR-23-1180.
CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
Hickman R, Gedvilaite E, Ptashkin R, Reiner A, Cimera R, Nandakumar S
Acta Neuropathol. 2023; 146(6):845-847.
PMID: 37831210
PMC: 10628020.
DOI: 10.1007/s00401-023-02639-0.
Brain Plasticity Profiling as a Key Support to Therapeutic Decision-Making in Low-Grade Glioma Oncological Strategies.
Ng S, Duffau H
Cancers (Basel). 2023; 15(14).
PMID: 37509359
PMC: 10378506.
DOI: 10.3390/cancers15143698.
Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas.
Kurimoto M, Rockenbach Y, Kato A, Natsume A
Genes (Basel). 2023; 14(6).
PMID: 37372381
PMC: 10298357.
DOI: 10.3390/genes14061201.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff I, van den Bent M, Blumenthal D, Touat M, Peters K, Clarke J
N Engl J Med. 2023; 389(7):589-601.
PMID: 37272516
PMC: 11445763.
DOI: 10.1056/NEJMoa2304194.
Predicting regrowth of low-grade gliomas after radiotherapy.
Plaszczynski S, Grammaticos B, Pallud J, Campagne J, Badoual M
PLoS Comput Biol. 2023; 19(3):e1011002.
PMID: 37000852
PMC: 10128962.
DOI: 10.1371/journal.pcbi.1011002.
Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol. 2023; 162(1):237-244.
PMID: 36913047
DOI: 10.1007/s11060-023-04288-5.
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.
Ozair A, Bhat V, Alisch R, Khosla A, Kotecha R, Odia Y
Cancers (Basel). 2023; 15(4).
PMID: 36831683
PMC: 9954183.
DOI: 10.3390/cancers15041342.